Huabo Biopharm (Shanghai) Co., Ltd.-新闻资讯

NEWS & MEDIA

13
2021-01

Certified as ‘Enterprise Research and Development Facility in Pudong New District’

Certified as ‘Enterprise Research and Development Facility in Pudong New District’

Press Releases
21
2020-12

HB0025 Injection Obtained FDA IND Approval for Phase I Clinical Trial

HB0025 Injection Obtained FDA IND Approval for Phase I Clinical Trial

Press Releases
04
2020-12

Multiple Innovative Projects Won Awards at ‘The First Science and Technology Festival’ Held by Huahai Pharmaceutical Co., Ltd.

Multiple Innovative Projects Won Awards at ‘The First Science and Technology Festival’ Held by Huahai Pharmaceutical Co., Ltd.

Press Releases
20
2020-10

First CategoryⅠof Therapeutic Biological Products Ophthalmic Injection HB002.1M Obtained NMPA IND Approval for Phase I Clinical Trial

First CategoryⅠof Therapeutic Biological Products Ophthalmic Injection HB002.1M Obtained NMPA IND Approval for Phase I Clinical Trial

Press Releases
29
2020-09

Three New Indications of HB002.1M Ophthalmic Injection Obtained NMPA IND Approval for Phase II Clinical Trial

Newly, 3 new indications of the recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection (HB002.1M) developed by Shanghai Huaota Bi...

Press Releases
25
2020-09

HOT-1030 Injection Obtained FDA IND Approval for Phase I Clinical Trial

Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (aka Huata) and its subsidiary Huabo Biopharm(Shanghai) Co., Ltd. (aka Huabo) received ‘investigational new drug approval notic...

Press Releases